796 related articles for article (PubMed ID: 20427430)
41. Trends in Treatment Patterns and Outcomes for Ductal Carcinoma In Situ.
Worni M; Akushevich I; Greenup R; Sarma D; Ryser MD; Myers ER; Hwang ES
J Natl Cancer Inst; 2015 Dec; 107(12):djv263. PubMed ID: 26424776
[TBL] [Abstract][Full Text] [Related]
42. Prognostic significance of oncogenic markers in ductal carcinoma in situ of the breast: a clinicopathologic study.
Altintas S; Lambein K; Huizing MT; Braems G; Asjoe FT; Hellemans H; Van Marck E; Weyler J; Praet M; Van den Broecke R; Vermorken JB; Tjalma WA
Breast J; 2009; 15(2):120-32. PubMed ID: 19292797
[TBL] [Abstract][Full Text] [Related]
43. Comparison of ipsilateral breast tumor recurrence after breast-conserving surgery between ductal carcinoma in situ and invasive breast cancer.
Choi YJ; Shin YD; Song YJ
World J Surg Oncol; 2016 Apr; 14():126. PubMed ID: 27122132
[TBL] [Abstract][Full Text] [Related]
44. Is there a low-grade precursor pathway in breast cancer?
King TA; Sakr RA; Muhsen S; Andrade VP; Giri D; Van Zee KJ; Morrow M
Ann Surg Oncol; 2012 Apr; 19(4):1115-21. PubMed ID: 21935747
[TBL] [Abstract][Full Text] [Related]
45. Tumor thickness and histological features as predictors of invasive foci within preoperatively diagnosed ductal carcinoma in situ.
Mori K; Takeda M; Kodama Y; Kiyokawa H; Yasojima H; Mizutani M; Otani Y; Morikawa N; Masuda N; Mano M
Hum Pathol; 2017 Jun; 64():145-155. PubMed ID: 28434924
[TBL] [Abstract][Full Text] [Related]
46. Triple-negative and HER2 positive ductal carcinoma in situ of the breast: characteristics, behavior, and biomarker profile.
Takahashi S; Thike AA; Koh VCY; Sasano H; Tan PH
Virchows Arch; 2018 Sep; 473(3):275-283. PubMed ID: 30033510
[TBL] [Abstract][Full Text] [Related]
47. Estrogen-receptor status and risk of contralateral breast cancer following DCIS.
Stout NK; Cronin AM; Uno H; Ozanne EM; Hassett MJ; Frank ES; Greenberg CC; Punglia RS
Breast Cancer Res Treat; 2018 Oct; 171(3):777-781. PubMed ID: 29946862
[TBL] [Abstract][Full Text] [Related]
48. Biologic markers in ductal carcinoma in situ and concurrent infiltrating carcinoma. A comparison of eight contemporary grading systems.
Leong AS; Sormunen RT; Vinyuvat S; Hamdani RW; Suthipintawong C
Am J Clin Pathol; 2001 May; 115(5):709-18. PubMed ID: 11345835
[TBL] [Abstract][Full Text] [Related]
49. Long-Term Outcomes of Immunohistochemically Defined Subtypes of Breast Cancer Less Than or Equal to 2 cm After Breast-Conserving Surgery.
Pata G; Guaineri A; Bianchi A; Amoroso V; Pasinetti N; Pasini M
J Surg Res; 2019 Apr; 236():288-299. PubMed ID: 30694768
[TBL] [Abstract][Full Text] [Related]
50. Differences in the pathologic and molecular features of intraductal breast carcinoma between younger and older women.
Rodrigues NA; Dillon D; Carter D; Parisot N; Haffty BG
Cancer; 2003 Mar; 97(6):1393-403. PubMed ID: 12627502
[TBL] [Abstract][Full Text] [Related]
51. Keratin 17 is overexpressed and predicts poor survival in estrogen receptor-negative/human epidermal growth factor receptor-2-negative breast cancer.
Merkin RD; Vanner EA; Romeiser JL; Shroyer ALW; Escobar-Hoyos LF; Li J; Powers RS; Burke S; Shroyer KR
Hum Pathol; 2017 Apr; 62():23-32. PubMed ID: 27816721
[TBL] [Abstract][Full Text] [Related]
52. Factors influencing agreement of breast cancer luminal molecular subtype by Ki67 labeling index between core needle biopsy and surgical resection specimens.
Tendl-Schulz KA; Rössler F; Wimmer P; Heber UM; Mittlböck M; Kozakowski N; Pinker K; Bartsch R; Dubsky P; Fitzal F; Filipits M; Eckel FC; Langthaler EM; Steger G; Gnant M; Singer CF; Helbich TH; Bago-Horvath Z
Virchows Arch; 2020 Oct; 477(4):545-555. PubMed ID: 32383007
[TBL] [Abstract][Full Text] [Related]
53. Subsequent risk of ipsilateral and contralateral invasive breast cancer after treatment for ductal carcinoma in situ: incidence and the effect of radiotherapy in a population-based cohort of 10,090 women.
Elshof LE; Schaapveld M; Schmidt MK; Rutgers EJ; van Leeuwen FE; Wesseling J
Breast Cancer Res Treat; 2016 Oct; 159(3):553-63. PubMed ID: 27624164
[TBL] [Abstract][Full Text] [Related]
54. Distant invasive breast cancer recurrence risk in human epidermal growth factor receptor 2-positive T1a and T1b node-negative localized breast cancer diagnosed from 2000 to 2006: a cohort from an integrated health care delivery system.
Fehrenbacher L; Capra AM; Quesenberry CP; Fulton R; Shiraz P; Habel LA
J Clin Oncol; 2014 Jul; 32(20):2151-8. PubMed ID: 24888815
[TBL] [Abstract][Full Text] [Related]
55. Pathological underestimation and biomarkers concordance rates in breast cancer patients diagnosed with ductal carcinoma in situ at preoperative biopsy.
Zhou H; Yu J; Wang X; Shen K; Ye J; Chen X
Sci Rep; 2022 Feb; 12(1):2169. PubMed ID: 35140303
[TBL] [Abstract][Full Text] [Related]
56. Comparative evaluation of the erbB2 and hormone receptor status of neighboring invasive and in situ components of ductal carcinomas of the breast.
Peres RM; Serra KP; Derchain SF; Yoon JH; Pinto GA; Alvarenga M; Soares FA; Heinrich JK; da Cunha IW; Vassallo J; Sarian LO
Int J Biol Markers; 2009; 24(4):238-44. PubMed ID: 20108215
[TBL] [Abstract][Full Text] [Related]
57. Ten-year risk of diagnostic mammograms and invasive breast procedures after breast-conserving surgery for DCIS.
Nekhlyudov L; Habel LA; Achacoso N; Jung I; Haque R; Collins LC; Schnitt SJ; Quesenberry CP; Fletcher SW
J Natl Cancer Inst; 2012 Apr; 104(8):614-21. PubMed ID: 22491230
[TBL] [Abstract][Full Text] [Related]
58. Biological markers that predict clinical recurrence in ductal carcinoma in situ of the breast.
Provenzano E; Hopper JL; Giles GG; Marr G; Venter DJ; Armes JE
Eur J Cancer; 2003 Mar; 39(5):622-30. PubMed ID: 12628841
[TBL] [Abstract][Full Text] [Related]
59. Alterations of ER, PR, HER-2/neu, and P53 protein expression in ductal breast carcinomas and clinical implications.
Liu C; Zhang H; Shuang C; Lu Y; Jin F; Xu H; Lu P
Med Oncol; 2010 Sep; 27(3):747-52. PubMed ID: 19657752
[TBL] [Abstract][Full Text] [Related]
60. Distinguishing luminal breast cancer subtypes by Ki67, progesterone receptor or TP53 status provides prognostic information.
Feeley LP; Mulligan AM; Pinnaduwage D; Bull SB; Andrulis IL
Mod Pathol; 2014 Apr; 27(4):554-61. PubMed ID: 24051696
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
